Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Developing Oral LT3 Therapy For Heart Failure With Preserved Ejection Fraction

NCT04111536 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.

NCT NCT04111536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04111536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Developing Oral LT3 Therapy For Heart Failure With Preserved Ejection Fraction
Lead sponsor
University of Pennsylvania
Phase
Phase 1/2
Overall status
Completed
Start date
March 8, 2020
Completion date
October 31, 2023
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction, low triiodothyronine syndrome